小嬿你覺得利用過年期間做一個這樣的實驗怎麼樣:仿老師們建議去transform PBMC (Gosh, it takes four weeks!這裡)的實驗,但是我們利用G418(Akata)或hygromycin(Maxi)的抗藥性做在293上。就是說類似這次做法把infection(24-well~0.5-ml cell)做完後的細胞,稀釋到含藥(maintain時的雙倍濃度)的150-mm盤子裡。如果它們是真貨的話,會被留下來產生colony.過了完年後我們也有了immortaized-HEK293 cells⁈
2009/03/04 Dr. Lin’s laboratory is directed at studying the oncogenic mechanisms of human herpesviruses including EBV and KSHV: (1) it is not completely understood why only the minority of EBV infected individuals suffered from cancers, while the majority can be waived; (2) it is mysterious why most of the reported EBV and KSHV encoded onco-proteins
如題。本是想進來close-up、清除網際垃圾的,但看了智興有留言,就手癢又回了二則comment。接著心血來潮,覺得李老師啊、靜娟、能耀、柯俊、及那些忙碌的醫師們會不會有興趣以blog溝通?像這樣:親愛的各位,這裡有一篇好文,教人如何處理genome-wide data,在bioinformatician還未找到前,是一篇可以自修的功課。有人反對我邀請台南的同仁加入嗎?有多少人贊成我關網?(目前還是有二人沒有接受邀請、所以算二票)
想必各位have received the message from Dr. L-T Chen. 我個人沒意願，因為我只想快樂地做研究，我不想花太多時間在寫計畫及報告，我也沒意願去跟很多不了解甚至不認識的人合作。
xlsx converter http://www.zamzar.com/ Gene ontological classification9 of the differentially expressed genes was performed by using the DAVID Bioinformatics Database functional-annotation tools (http://david.abcc.ncifcrf.gov/)30. The microarray data have been deposited in the Gene Expression Omnibus maintained by the US National Center for Biotechnology Information (http://www.ncbi.nlm.nih.gov/geo/). Accession numbers. Gene Expression Omnibus series GSE9167. ———————————————(a) Venn diagram of genes
(1) 每筆Recent comment最後一行註明留言人的hyperlink按一下,就可追到這筆回應的相對po文。(2) 開文時下方有個 “Labels for this post”,請填個名稱以利分類。(3) 第一名進網的夏博士還沒有張文呢—期待喔~
我已經有跟榮總大夫聯絡上，合作關係的建立應該沒問題。請問各位想從何時開始聽聽臨床的見解？有機會的話，我也想請陳立宗副主任來講一下，如何？
請問各位想從何時開始聽聽臨床的見解？ Read More »
From 文祥’s 草稿：(1) Individual’s interests:智興-pancreatic ca, 界元-pancreatic ca, 美霞-pancreatic ca, 興國-oral ca followed by pancreatic, 文祥/素芳-皆可,服從多數決。(2)粗分三項(A)clinical therapy(B)tumor marker (智興、美霞、界元+?)(C)tumor biology (興國、雙恩、界元、素芳+?)(文祥我忘了你該在哪,sorry)(3)申請金額35~50k/individual都有人建議。(4)黃博士述及與榮總合作經驗(5)夏博士述及與三總合作經驗(6)論及與tainanbop合作模式(7)待確定事項:陳老師、于老師是否加入(8)Group leader:任重道遠、無量功德、……建議組員輪流擔任